This cluster reflects a maturing research trajectory in which ketamine, esketamine, and classical/classic psychedelics (psilocybin, LSD, DMT, ayahuasca) are increasingly grouped under a unified psychedelic-psychiatric therapeutics paradigm, positioned as alternatives to inadequate standard treatments for treatment-resistant depression, anxiety and affective disorders, and end-of-life distress. Ketamine and esketamine are distinguished mechanistically as NMDA receptor antagonists producing rapid-acting antidepressant effects, while classical psychedelics act primarily via serotonergic (5-HT) receptor agonism, altering functional connectivity and neural circuit activity implicated in mood, cognition, and perception. The convergence of glutamatergic, serotonergic, and neurotrophic signaling pathways is emerging as a shared biological substrate for rapid and durable antidepressant action, directly informing the design of next-generation rapid-acting antidepressants that may combine or bypass the dissociative/hallucinogenic liabilities of current agents.
Clinically, the field is moving beyond pure pharmacology toward structured psychotherapeutic frameworks—preparation, dosing, and integration phases—supported by multidisciplinary teams including chaplains and trained healthcare providers who foster therapeutic presence, insight, ego dissolution processing, and identity exploration. Constructs like the Psychedelic Harm Reduction and Integration model and qualitative thematic frameworks ("The Art of Being-There," "Reflect on Your Biases and Learn the Language") signal growing attention to relational and contextual factors (set and setting) as co-determinants of outcome alongside receptor pharmacology. This is paralleled by survey-based research probing patient, clinician, and general-population knowledge, attitudes, and concerns regarding legality, risk, and clinical acceptability of both ketamine and classical psychedelics—suggesting an implementation-science phase is beginning alongside mechanistic discovery.
Simultaneously, a risk-stratification narrative is developing: overdose, polydrug use, unstructured settings, psychosocial stress, and pre-existing psychiatric vulnerability are identified as risk factors for persisting anxiety and affective disorders following psychedelic use, and challenging experiences are quantified against mystical experiences and emotional breakthroughs as predictors of wellbeing outcomes. Death and adverse-event data involving LSD and DMT (psychedelic tryptamines) further underscore the need for safety-focused protocols. Together, these threads point toward a bifurcated but complementary trend: deepening neurobiological convergence models (serotonergic–glutamatergic–neurotrophic) driving drug development, alongside expanding psychosocial/therapeutic infrastructure and public-attitude research aimed at responsible clinical translation across depression, anxiety, fibromyalgia, cluster headache, and end-of-life care indications.